 |
|
|
| |
12-month outcome of Dolutegravir/Rilpivirine in virologically suppressed HIV-infected patients: Real-world data from the German JUNGLE cohort
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Sebastian Noe1, Kevin Ummard-Berger2, Heribert Hillenbrand3, Daniel Beer4, Christoph Wyen5, Ramona Pauli6, Nils Postel7, Kathrin Maria Dymek8, Bernd Westermayer9, Jenny Scherzer8
1MVZ Karlsplatz, Munich, Germany; 2UBN/Praxis, Berlin, Germany; 3MVZ PraxisCityOst, Berlin, Germany; 4Praxis Dr. Knechten Aachen, Germany; 5Praxis Ebertplatz Cologne, Germany; 6Isarpraxis Munich, Germany; 7prinzmed, Munich, Germany; 8ViiV Healthcare, Munich, Germany; 9GlaxoSmithKline Munich, Germany
|
| |
|
|
|
|
|
